tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

DRMA Stock Latest News

Dermata achieves 50% enrollment in DMT310 Phase 3 STAR-1 clinical trial
The FlyDermata achieves 50% enrollment in DMT310 Phase 3 STAR-1 clinical trial
2d ago
DRMA
Dermata Therapeutics announces exercise of warrants for $2.66M
PremiumThe Fly
Dermata Therapeutics announces exercise of warrants for $2.66M
2M ago
DRMA
Dermata Therapeutics reports Q1 EPS (47c) vs. ($2.27) last year
PremiumThe Fly
Dermata Therapeutics reports Q1 EPS (47c) vs. ($2.27) last year
2M ago
DRMA
Dermata Therapeutics Inc trading halted, news pending
PremiumThe Fly
Dermata Therapeutics Inc trading halted, news pending
2M ago
DRMA
Dermata Therapeutics Unveils Key Financial Results and Efficiencies
PremiumCompany Announcements
Dermata Therapeutics Unveils Key Financial Results and Efficiencies
2M ago
8K
DRMA
Dermata Therapeutics Enhances Equity Plan and Approves Stock Split
PremiumCompany AnnouncementsDermata Therapeutics Enhances Equity Plan and Approves Stock Split
2M ago
8K
DRMA
Dermata Therapeutics: Unveiling Recent Financial Performance
PremiumCompany Announcements
Dermata Therapeutics: Unveiling Recent Financial Performance
4M ago
8K
DRMA
Dermata Therapeutics up 93% at $1.18 after DMT410 Japan patent announcement
PremiumThe Fly
Dermata Therapeutics up 93% at $1.18 after DMT410 Japan patent announcement
7M ago
DRMA
Dermata Therapeutics issues new patent in Japan for DMT410 program
PremiumThe Fly
Dermata Therapeutics issues new patent in Japan for DMT410 program
7M ago
DRMA
Dermata Therapeutics files to sell 7.19M shares of common stock for holders
PremiumThe Fly
Dermata Therapeutics files to sell 7.19M shares of common stock for holders
7M ago
DRMA
Dermata Therapeutics to begin enrollment in DMT310 Phase 3 program in December
PremiumThe Fly
Dermata Therapeutics to begin enrollment in DMT310 Phase 3 program in December
8M ago
DRMA
Dermata Therapeutics files to sell 857K shares of common stock for holders
PremiumThe Fly
Dermata Therapeutics files to sell 857K shares of common stock for holders
1y ago
DRMA
Dermata announces FDA feedback on DMT310 Phase 3 development program
PremiumThe FlyDermata announces FDA feedback on DMT310 Phase 3 development program
1y ago
DRMA
Dermata Therapeutics price target lowered to $4 from $16 at Maxim
PremiumThe Fly
Dermata Therapeutics price target lowered to $4 from $16 at Maxim
1y ago
DRMA
Dermata Therapeutics price target lowered to $1 from $4 at Maxim
PremiumThe Fly
Dermata Therapeutics price target lowered to $1 from $4 at Maxim
2y ago
DRMA
Dermata Therapeutics down 49% after results from DMT310 Phase 2 trial
PremiumThe Fly
Dermata Therapeutics down 49% after results from DMT310 Phase 2 trial
2y ago
DRMA
Dermata Therapeutics announces results from DMT310 Phase 2 trial
PremiumThe Fly
Dermata Therapeutics announces results from DMT310 Phase 2 trial
2y ago
DRMA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >